Galmed Pharmaceuticals Ltd (GLMD) - Total Liabilities
Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has total liabilities worth $5.54 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Galmed Pharmaceuticals Ltd (GLMD) investment intensity to see how much of total assets are deployed in long-term investments.
Galmed Pharmaceuticals Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Galmed Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Galmed Pharmaceuticals Ltd total assets.
Galmed Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silver Grail Resources Ltd
V:SVG
|
Canada | CA$429.74K |
|
Argentum Silver Corp
V:ASL
|
Canada | CA$472.82K |
|
FUTURE METALS NL
F:3R10
|
Germany | €381.80K |
|
Adslot Ltd
AU:ADS
|
Australia | AU$9.92 Million |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
Indonesia | Rp797.31 Billion |
|
Tsodilo Resources Limited
V:TSD
|
Canada | CA$4.45 Million |
|
Reliance Global Group Inc
NASDAQ:RELI
|
USA | $6.37 Million |
|
Wah Fu Education Group Ltd
NASDAQ:WAFU
|
USA | $3.16 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Galmed Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Galmed Pharmaceuticals Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galmed Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual total liabilities of Galmed Pharmaceuticals Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.85 Million | +30.92% |
| 2024-12-31 | $2.17 Million | -20.98% |
| 2023-12-31 | $2.75 Million | -12.36% |
| 2022-12-31 | $3.14 Million | -48.62% |
| 2021-12-31 | $6.11 Million | -25.77% |
| 2020-12-31 | $8.23 Million | +12.93% |
| 2019-12-31 | $7.29 Million | +169.25% |
| 2018-12-31 | $2.71 Million | -29.68% |
| 2017-12-31 | $3.85 Million | -28.41% |
| 2016-12-31 | $5.38 Million | +97.76% |
| 2015-12-31 | $2.72 Million | +79.05% |
| 2014-12-31 | $1.52 Million | -28.29% |
| 2013-12-31 | $2.12 Million | -22.77% |
| 2012-12-31 | $2.74 Million | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more